Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V940 plus pembrolizumab with or without enfortumab vedotin in muscle-invasive urothelial carcinoma
2023-505658-17-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised trial of intismeran autogene, pembrolizumab and enfortumab vedotin in transitional cell carcinoma (TCC) and muscle-invasive bladder cancer (MIBC) (4 arms), sponsored by Merck & Co. Primary endpoints: Disease-Free Survival, Number of participants who experience an adverse event and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2023-505658-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505658-17-00.